Little Green Pharma (LGP) has said it will remain one of only two authorised suppliers into the French market for at least another year, as authorities in Paris formally released a blueprint for a medical cannabis market to the European Commission (EC).
LGP said the document sent to the EC is a “critical step” towards establishing a “pathway for regulatory approval and structured market access”.
Under the framework, all medicinal cannabis products in France will require a Common Technical Document (CTD) to be eligible to be prescribed.
LGP said the “significant information and data requirements” of the CTD will result in few players entering the market.
A transition period has been extended until March 31, 2026 “during which time LGP will continue to be one of only two company’s supplying products at full price”.
The WA-based firm has long spruiked its involvement in a medicinal cannabis trial in France, telling investors its early move into the market has set itself up for long-term success.
It has been supplying product into France since 2021.
“Leveraging its extensive experience and strong partnerships with French distributors, healthcare providers and regulatory authorities, LGP is well-positioned to capitalise on the evolving market landscape,” it said.
“This development underscores LGP’s long-term strategic vision for France and reaffirms its commitment to supplying high-quality medicinal cannabis products to patients in need.”
